Français
Español
English
Portuguese
Initial sales of that dural repair graft have started in the United States, giving the company its first foothold in the US market.
By Shula Rosen
Nurami Medical says it is closing in on human trials for a new surgical patch meant to seal the membrane that protects the brain and spinal cord — a routine but critical step in many neurosurgeries — after clearing major regulatory and development hurdles in Europe.
The Haifa-based company announced it has completed the first phase of work on Artifix, a synthetic dural repair patch designed to help surgeons quickly and securely close the dura during brain and spinal procedures.
The milestone was achieved under a grant from the European Innovation Council and positions the product to enter first-in-human clinical trials by the end of 2025.
Company officials said the completed phase included laboratory testing, preparation of regulatory files and initial approvals from European countries expected to host the trials. With those steps finished, Artifix is now moving from the development stage toward clinical use.
“Successfully completing these milestones brings Artifix much closer to the operating room,” said Dr. Amir Bahar, Nurami’s chief commercial officer and co-founder, in a press release. He said the product reflects the company’s focus on improving surgical tools rather than developing drugs or biological implants.
While clinical approvals are still pending, Nurami has already begun laying the groundwork for adoption. The company said it has been meeting with neurosurgeons in Europe and the United States and presenting the product concept at major international conferences to gather early feedback and build awareness ahead of trials.
The progress on Artifix comes as Nurami begins commercial activity for its first product, ArtiFascia, which recently received clearance from US regulators.
Initial sales of that dural repair graft have started in the United States, giving the company its first foothold in the US market.
Nurami also confirmed it has secured Phase 2 funding from the European Innovation Council, allowing development to continue as the company transitions into clinical testing. Executives said the continued backing reflects confidence in both the technology and the company’s broader strategy.
Founded in Haifa, Nurami Medical develops synthetic materials for surgical tissue repair, targeting areas where surgeons need durable, easy-to-use solutions. Company officials said advancing one product toward human trials while another enters the market marks a shift from pure development to execution.
The next test, they say, will be whether Artifix can prove its value in real surgical settings — and help simplify a procedure neurosurgeons perform thousands of times each year.
Do You Love Israel? Make a Donation - Show Your Support!
Donate to vital charities that help protect Israeli citizens and inspire millions around the world to support Israel too!
Now more than ever, Israel needs your help to fight and win the war -- including on the battlefield of public opinion.
Antisemitism, anti-Israel bias and boycotts are out of control. Israel's enemies are inciting terror and violence against innocent Israelis and Jews around the world. Help us fight back!
